Clinical Trial Info

COVID-19 Study Assessing the Virologic Efficacy of REGN10933+REGN10987 Across Different Dose Regimens in Adult Outpatients With SARS-CoV-2 Infection

Authored by
Staff

The primary objective of the Phase 2 study is to assess the virologic efficacy of REGN10933+REGN10987 across different intravenous and subcutaneous doses compared to placebo.

The secondary objectives of the study are:

To evaluate additional indicators of virologic efficacy of REGN10933+REGN10987 compared to placebo

To evaluate the safety and tolerability of REGN10933+REGN10987 compared to placebo

To assess the concentrations of REGN10933 and REGN10987 in serum over time

To assess the immunogenicity of REGN10933 and REGN10987